Approximately 150 subjects will be enrolled, receiving either the therapy or a placebo daily for a 52-week treatment period.

Parse Biosciences today announced their commitment to support researchers from the Icahn School of Medicine at Mount Sinai in gen ...

A new study has found that regular use of certain types of commonly-prescribed drugs can increase the risk of dementia in ...

Researchers have developed a gene therapy that significantly slowed motor function loss in preclinical models of amyotrophic ...

June is Alzheimer’s and Brain Health Awareness Month. More than 7 million people have Alzheimer’s disease here in the United States. Now, a new blood test may be able to help with early diagnosis.

The study, carried out by experts from the University of Nottingham and funded by the National Institute for Health Research ...

Now, researchers are turning to an unexpected source for early PDAC detection: faecal samples. While analysing poo might seem ...

Dr. Bernick says since this blood test can help with early diagnosis, it gives a person the chance to start treatment sooner.

SUNRISE-PD is a Phase 2b, multicenter, randomized, double-blind, placebo-controlled trial with a hybrid decentralized design that will last 20 weeks from the initial screening phase to the safety ...

British actress Sophie Turner began her ascent into stardom at the age of thirteen when she got a role in the critically ...